RA Capital Management, LP (RA Capital), a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies, today ...

Shares of AbbVie Inc. ABBV slipped 0.74% to $174.37 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.82% to 6,084.19 and ...

AbbVie has completed its acquisition of Aliada Therapeutics which includes Aliada’s disease-modifying therapy for Alzheimer’s disease.

AbbVie Inc. is a strong investment opportunity with promising drugs, steady dividends, and attractive growth potential. Find ...

AbbVie Inc (ABBV) stock saw a decline, ending the day at $175.67 which represents a decrease of $-0.90 or -0.51% from the prior close of $176.57. The stock opened at $175.53 and touched a low of $173.

Immunome has a turbulent history, shifting focus from COVID-19 therapies to oncology. Read what the future may hold for this ...

AnaptysBio will end the development of its experimental drug to treat eczema as the treatment failed to meet the goals of a mid-stage trial, the company said on Wednesday, dragging its shares nearly ...

AbbVie (ABBV) announced that it has completed its acquisition of Aliada Therapeutics. With the completion of the acquisition, Aliada is now a ...

Recently the National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre (BRC) and the NIHR North West Regional Research Delivery Network collaboratively hosted the ...

The Pistoia Alliance, a global, not-for-profit alliance that advocates for greater collaboration in life sciences R&D, has announced the results of a global survey in conjunction with CCC (Copyright ...

Apimostinel has a similar mode of action to ketamine and derivatives like Johnson & Johnson's Spravato (esketamine) – ...

GSK, Gilead and Arcellx, Vertex and more present new data at the American Society of Hematology annual meeting just as sickle cell therapies Casgevy and Lyfgenia have a new outcomes-based payment ...